193 related articles for article (PubMed ID: 8397766)
1. Immunotoxins: magic bullets or misguided missiles?
Vitetta ES; Thorpe PE; Uhr JW
Immunol Today; 1993 Jun; 14(6):252-9. PubMed ID: 8397766
[TBL] [Abstract][Full Text] [Related]
2. Immunotoxins: magic bullets or misguided missiles?
Vitetta ES; Thorpe PE; Uhr JW
Trends Pharmacol Sci; 1993 May; 14(5):148-54. PubMed ID: 8212309
[TBL] [Abstract][Full Text] [Related]
3. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic use of immunotoxins.
Cobb PW; LeMaistre CF
Semin Hematol; 1992 Jul; 29(3 Suppl 2):6-13. PubMed ID: 1509295
[TBL] [Abstract][Full Text] [Related]
5. Future prospects of monoclonal antibodies as magic bullets in immunotherapy.
Maleki LA; Baradaran B; Majidi J; Mohammadian M; Shahneh FZ
Hum Antibodies; 2013; 22(1-2):9-13. PubMed ID: 24284304
[TBL] [Abstract][Full Text] [Related]
6. Rationale for clinical use of immunotoxins in cancer and autoimmune disease.
Byers VS; Baldwin RW
Semin Cell Biol; 1991 Feb; 2(1):59-70. PubMed ID: 1954344
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies in cancer immunotherapy.
Reisfeld RA
Clin Lab Med; 1992 Jun; 12(2):201-16. PubMed ID: 1611818
[TBL] [Abstract][Full Text] [Related]
8. Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins.
Shapira S; Lisiansky V; Arber N; Kraus S
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S67-77. PubMed ID: 20374033
[TBL] [Abstract][Full Text] [Related]
9. Immunotoxin therapy of cancer.
Frankel AE
Oncology (Williston Park); 1993 May; 7(5):69-78; discussion 79-80, 83-6. PubMed ID: 8512787
[TBL] [Abstract][Full Text] [Related]
10. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology].
Chiron MF
Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366
[TBL] [Abstract][Full Text] [Related]
11. [Cancer therapy by using bispecific antibody].
Azuma A; Niitani H; Okumura K
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1535-42. PubMed ID: 1872618
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.
Henry CJ; Buss MS; Hellström I; Hellström KE; Brewer WG; Bryan JN; Siegall CB
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):751-5. PubMed ID: 15701865
[TBL] [Abstract][Full Text] [Related]
13. Immunotoxins and cytokine toxin fusion proteins.
Strom TB; Anderson PL; Rubin-Kelley VE; Williams DP; Kiyokawa T; Murphy JR
Semin Immunol; 1990 Nov; 2(6):467-79. PubMed ID: 2104283
[TBL] [Abstract][Full Text] [Related]
14. [Use of monoclonal antibodies in the immunotherapy of neoplasms].
Robak T
Przegl Lek; 1989; 46(4):420-6. PubMed ID: 2672121
[No Abstract] [Full Text] [Related]
15. [Immunotoxins].
Gedikoğlu S
Mikrobiyol Bul; 1990 Jan; 24(1):79-87. PubMed ID: 2283968
[TBL] [Abstract][Full Text] [Related]
16. Immunotoxins to the murine transferrin receptor: intracavitary therapy of mice bearing syngeneic peritoneal tumors.
Bjorn MJ; Groetsema G
Cancer Res; 1987 Dec; 47(24 Pt 1):6639-45. PubMed ID: 3499979
[TBL] [Abstract][Full Text] [Related]
17. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
18. [Recombinant immunotoxin for cancer therapy: current status and prospective].
Nagata S
Tanpakushitsu Kakusan Koso; 2001 Mar; 46(4 Suppl):540-6. PubMed ID: 11268658
[No Abstract] [Full Text] [Related]
19. [Immunotoxin: from the idea of "magic bullets" to clinical applications].
Engert A; Thorpe P
Med Klin (Munich); 1990 Sep; 85(9):555-60. PubMed ID: 2233614
[No Abstract] [Full Text] [Related]
20. Targeted antibodies in the treatment of lymphomas.
Falini B; Terenzi A; Liso A; Flenghi L; Solinas A; Pasqualucci L
Cancer Surv; 1997; 30():295-309. PubMed ID: 9547998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
